RS50185B - Primena derivata fumarne kiseline u lečenju mitohondrijalnih bolesti - Google Patents
Primena derivata fumarne kiseline u lečenju mitohondrijalnih bolestiInfo
- Publication number
- RS50185B RS50185B YUP-514/02A YUP51402A RS50185B RS 50185 B RS50185 B RS 50185B YU P51402 A YUP51402 A YU P51402A RS 50185 B RS50185 B RS 50185B
- Authority
- RS
- Serbia
- Prior art keywords
- fumaric acid
- disease
- acid derivatives
- mitochondrial
- fumaric
- Prior art date
Links
- 150000002237 fumaric acid derivatives Chemical class 0.000 title abstract 4
- 208000012268 mitochondrial disease Diseases 0.000 title abstract 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 8
- 150000002148 esters Chemical class 0.000 abstract 4
- 239000001530 fumaric acid Substances 0.000 abstract 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 4
- 239000002253 acid Substances 0.000 abstract 2
- 150000001768 cations Chemical class 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 abstract 1
- 206010034010 Parkinsonism Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- -1 alkyl radical Chemical class 0.000 abstract 1
- 150000005840 aryl radicals Chemical class 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003254 radicals Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 230000007704 transition Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Primena pojedinačnih ili smeše derivata fumarne kiseline za pripremanje farmaceutske kompozicije za lečenje mitohondrijalnih bolesti, što su derivati fumarne kiseline oni koji su odabrani od grupe sastavljene iz dialkilestara fumarne kiseline i monoalkilestara fumarne kiseline u obliku slobodne kiseline ili njihove soli, pri čemu navedeni dialkilestar fumarne kiseline odgovara formuli pri čemu Rl i R2 mogu biti isti ili različiti, nezavisno jedan od drugog znače linearni, račvasti, ciklični, zasićeni ili nezasićeni Cl-24 alkil-ostatak ili jedan C5-20 aril-ostatak a ovi ostatci su u datom slučaju supstituisani halogenom (F, Cl, Br, J), hidroksi, Cl-4 alkoksi, nitro ili cijano, ili gde monoalkilestar fumarne kiseline odgovara formuli u kojoj: - Rl je kako je gore definisano, -A je vodonik ili alkalni ili zemnoalkalni katjon ili fiziološki podnošljivi katjon prelaznog elementa prevashodno izabran između Li+, Na+,K+, Mg2+, Ca2+, Zn2+,Fe2+,Mn2+ i -n je jednako 1 ili 2 i odgovara valenci od A, pri čemu je navedena mitohondrijalna bolest Parkinson-ov sindrom, Alzheimer-ova bolest, Chorea-Huntington-ova bolest, pigmentozna retinopatija ili mitohondrijalna encefalomiopatija, naznačena time, da jedinična doza sadrži količinu derivata fumarne kiseline koji odgovara sa 1 do 500 mg fumarne kiseline. Prijava sadrži još 8 patentnih zahteva.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10000577A DE10000577A1 (de) | 2000-01-10 | 2000-01-10 | Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| YU51402A YU51402A (sh) | 2006-01-16 |
| RS50185B true RS50185B (sr) | 2009-05-06 |
Family
ID=7627026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YUP-514/02A RS50185B (sr) | 2000-01-10 | 2000-12-11 | Primena derivata fumarne kiseline u lečenju mitohondrijalnih bolesti |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6858750B2 (sr) |
| EP (1) | EP1248606B1 (sr) |
| JP (1) | JP2003529556A (sr) |
| CN (1) | CN1433303A (sr) |
| AT (1) | ATE329590T1 (sr) |
| AU (1) | AU772409B2 (sr) |
| BG (1) | BG65468B1 (sr) |
| BR (1) | BR0016935A (sr) |
| CA (1) | CA2390886C (sr) |
| CY (1) | CY1105462T1 (sr) |
| CZ (1) | CZ303680B6 (sr) |
| DE (2) | DE10000577A1 (sr) |
| DK (1) | DK1248606T3 (sr) |
| EE (1) | EE05051B1 (sr) |
| ES (1) | ES2265367T3 (sr) |
| HU (1) | HU229138B1 (sr) |
| IL (2) | IL150516A0 (sr) |
| MX (1) | MXPA02006695A (sr) |
| NO (1) | NO326875B1 (sr) |
| NZ (1) | NZ518781A (sr) |
| PL (1) | PL223342B1 (sr) |
| PT (1) | PT1248606E (sr) |
| RS (1) | RS50185B (sr) |
| RU (1) | RU2218918C1 (sr) |
| SI (1) | SI1248606T1 (sr) |
| SK (1) | SK286719B6 (sr) |
| WO (1) | WO2001051047A1 (sr) |
| ZA (1) | ZA200205481B (sr) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19853487A1 (de) * | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| PL392750A1 (pl) * | 2001-01-12 | 2011-05-23 | Fumapharm Ag | Amidy kwasu fumarowego |
| DE10101307A1 (de) * | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
| DE10217314A1 (de) * | 2002-04-18 | 2003-11-13 | Fumapharm Ag Muri | Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere |
| US7224426B2 (en) * | 2002-07-31 | 2007-05-29 | Dai Nippon Printing Co., Ltd. | Optical element |
| PL1663197T3 (pl) * | 2003-09-09 | 2008-09-30 | Biogen Idec Int Gmbh | Zastosowanie pochodnych kwasu fumarowego do leczenia niewydolności serca oraz astmy |
| DE202005022112U1 (de) * | 2004-10-08 | 2014-04-24 | Forward Pharma A/S | Pharmazeutische Zusammensetzungen mit kontrollierter Freisetzung, umfassend einen Fumarsaureester |
| DE602006011910D1 (de) * | 2005-07-07 | 2010-03-11 | Aditech Pharma Ag | Neue glucopyranoseester und glucofuranoseester von fumarsäurealkylestern und deren pharmazeutische verwendung |
| WO2007006307A2 (en) * | 2005-07-07 | 2007-01-18 | Aditech Pharma Ab | Novel salts of fumaric acid monoalkylesters and their pharmaceutical use |
| JP5213137B2 (ja) * | 2006-12-06 | 2013-06-19 | コーネル リサーチ ファウンデーション， インコーポレイテッド | 中程度の持続時間の神経筋遮断剤およびそのアンタゴニスト |
| EP4137819A1 (en) | 2007-02-08 | 2023-02-22 | Biogen MA Inc. | Compositions and uses for treating multiple sclerosis |
| WO2008096271A2 (en) * | 2007-02-08 | 2008-08-14 | Ralf Gold | Neuroprotection in demyelinating diseases |
| EP2334378B1 (en) * | 2008-08-19 | 2014-04-09 | XenoPort, Inc. | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
| US20120034274A1 (en) * | 2009-01-09 | 2012-02-09 | Forward Pharma A/S | Pharmaceutical composition comprising one or more fumaric acid esters |
| RU2743637C2 (ru) | 2009-01-09 | 2021-02-20 | Фвп Ип Апс | Фармацевтический состав, содержащий один или более эфиров фумаровой кислоты в разлагаемой матрице |
| US8592451B2 (en) | 2009-03-17 | 2013-11-26 | Cornell University | Reversible nondepolarizing neuromuscular blockade agents and methods for their use |
| CN102573794B (zh) | 2009-08-19 | 2017-03-15 | 康奈尔大学 | 供生理注射用的半胱氨酸 |
| WO2012149478A2 (en) * | 2011-04-28 | 2012-11-01 | Serket Pharma, Llc | Agents useful for treating friedreich's ataxia and other neurodegenerative diseases |
| RS56972B1 (sr) | 2011-06-08 | 2018-05-31 | Biogen Ma Inc | Postupak za pripremu visoko-čistog i kristalnog dimetil fumarata |
| EP2782561A1 (en) | 2011-11-24 | 2014-10-01 | Synthon BV | Controlled release particles comprising dimethyl fumarate |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
| AU2013203445C1 (en) * | 2012-02-07 | 2017-04-20 | Biogen Ma Inc. | Pharmaceutical compositions containing dimethyl fumarate |
| NZ629728A (en) | 2012-02-07 | 2016-07-29 | Xenoport Inc | Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use |
| CA2882713A1 (en) | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
| EP2887933A1 (en) | 2012-08-22 | 2015-07-01 | XenoPort, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
| ES2733961T3 (es) | 2012-12-21 | 2019-12-03 | Biogen Ma Inc | Derivados de fumarato sustituidos con deuterio |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| RS57497B1 (sr) | 2013-03-14 | 2018-10-31 | Alkermes Pharma Ireland Ltd | Prolekovi fumarata i njihova upotreba u lečenju raznih bolesti |
| WO2014160633A1 (en) | 2013-03-24 | 2014-10-02 | Xenoport, Inc. | Pharmaceutical compositions of dimethyl fumarate |
| US9302977B2 (en) | 2013-06-07 | 2016-04-05 | Xenoport, Inc. | Method of making monomethyl fumarate |
| WO2014205392A1 (en) | 2013-06-21 | 2014-12-24 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| EP3041467A1 (en) | 2013-09-06 | 2016-07-13 | XenoPort, Inc. | Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use |
| AU2015218587B2 (en) | 2014-02-24 | 2017-04-27 | Alkermes Pharma Ireland Limited | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| WO2016061393A1 (en) | 2014-10-15 | 2016-04-21 | Xenoport, Inc. | Fumarate compounds, pharmaceutical compositions, and methods of use |
| HUE055210T2 (hu) | 2015-02-08 | 2021-11-29 | Alkermes Pharma Ireland Ltd | Monometilfumarát prodrug készítmények |
| ES2826825T3 (es) | 2015-03-27 | 2021-05-19 | Symbionyx Pharmaceuticals Inc | Composiciones y métodos para el tratamiento de la psoriasis |
| US10085961B2 (en) | 2015-06-01 | 2018-10-02 | Sun Pharmaceutical Industries Limited | Pharmaceutical compositions of dimethyl fumarate |
| WO2017060400A1 (en) | 2015-10-07 | 2017-04-13 | Neurovive Pharmaceutical Ab | Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions |
| IT201700087359A1 (it) | 2017-07-28 | 2019-01-28 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale |
| IT201700087376A1 (it) | 2017-07-28 | 2019-01-28 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale |
| RU2674286C1 (ru) * | 2018-03-20 | 2018-12-07 | Исмагилов Искандар Халиуллович | Средство для лечения заболевания, обусловленного нарушением окислительного стресса |
| RU2742745C1 (ru) * | 2019-09-24 | 2021-02-10 | Акционерное общество "Исследовательский Институт Химического Разнообразия" | Лекарственная форма в виде капсулы, содержащая таблетки с диметилфурмаратом |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2530372A1 (de) * | 1975-07-08 | 1977-01-13 | Walter Dr Schweckendiek | Pharmazeutische zubereitungen zur behandlung von psoriasis |
| DE2621214C3 (de) * | 1976-05-13 | 1981-11-12 | Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen | Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen |
| CH664150A5 (de) * | 1985-01-15 | 1988-02-15 | Peter Paul Prof Dr Speiser | Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen. |
| JPS61194020A (ja) * | 1985-02-22 | 1986-08-28 | Dai Ichi Seiyaku Co Ltd | 網膜症治療剤 |
| US4959389A (en) * | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
| IT1251166B (it) * | 1991-08-09 | 1995-05-04 | Chiesi Farma Spa | Derivati di geneserina,loro preparazione e composizioni farmaceutiche che li contengono |
| EP0750616B1 (en) * | 1994-03-16 | 2001-05-30 | CeNeS Limited | Acid addition salts of 2,3,4,5-tetrahydro-1h-3-benzazepine compounds |
| DE19721099C2 (de) * | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
| EP1032403B1 (en) * | 1997-10-24 | 2012-05-02 | John P. Blass | Nutritional supplement for cerebral metabolic insufficiencies |
| DE19839566C2 (de) * | 1998-08-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten in der Transplantationsmedizin |
| DE19853487A1 (de) * | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| US6812248B2 (en) * | 2000-07-05 | 2004-11-02 | John Hopkins University School Of Medicine | Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes |
-
2000
- 2000-01-10 DE DE10000577A patent/DE10000577A1/de not_active Withdrawn
- 2000-12-11 RU RU2002121493/15A patent/RU2218918C1/ru not_active IP Right Cessation
- 2000-12-11 MX MXPA02006695A patent/MXPA02006695A/es active IP Right Grant
- 2000-12-11 PL PL356714A patent/PL223342B1/pl unknown
- 2000-12-11 NZ NZ518781A patent/NZ518781A/en not_active IP Right Cessation
- 2000-12-11 US US10/148,858 patent/US6858750B2/en not_active Expired - Lifetime
- 2000-12-11 HU HU0204182A patent/HU229138B1/hu not_active IP Right Cessation
- 2000-12-11 ES ES00991160T patent/ES2265367T3/es not_active Expired - Lifetime
- 2000-12-11 SI SI200030869T patent/SI1248606T1/sl unknown
- 2000-12-11 BR BR0016935-8A patent/BR0016935A/pt not_active Application Discontinuation
- 2000-12-11 WO PCT/EP2000/012504 patent/WO2001051047A1/de active IP Right Grant
- 2000-12-11 PT PT00991160T patent/PT1248606E/pt unknown
- 2000-12-11 CA CA002390886A patent/CA2390886C/en not_active Expired - Fee Related
- 2000-12-11 EE EEP200200333A patent/EE05051B1/xx not_active IP Right Cessation
- 2000-12-11 RS YUP-514/02A patent/RS50185B/sr unknown
- 2000-12-11 SK SK652-2002A patent/SK286719B6/sk not_active IP Right Cessation
- 2000-12-11 CZ CZ20021522A patent/CZ303680B6/cs not_active IP Right Cessation
- 2000-12-11 JP JP2001551471A patent/JP2003529556A/ja active Pending
- 2000-12-11 IL IL15051600A patent/IL150516A0/xx active IP Right Grant
- 2000-12-11 EP EP00991160A patent/EP1248606B1/de not_active Expired - Lifetime
- 2000-12-11 AU AU31566/01A patent/AU772409B2/en not_active Ceased
- 2000-12-11 AT AT00991160T patent/ATE329590T1/de active
- 2000-12-11 DK DK00991160T patent/DK1248606T3/da active
- 2000-12-11 DE DE50013000T patent/DE50013000D1/de not_active Expired - Lifetime
- 2000-12-11 CN CN00818784A patent/CN1433303A/zh active Pending
-
2002
- 2002-05-07 NO NO20022175A patent/NO326875B1/no not_active IP Right Cessation
- 2002-05-09 BG BG106685A patent/BG65468B1/bg unknown
- 2002-07-02 IL IL150516A patent/IL150516A/en not_active IP Right Cessation
- 2002-07-09 ZA ZA200205481A patent/ZA200205481B/xx unknown
-
2006
- 2006-08-11 CY CY20061101141T patent/CY1105462T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS50185B (sr) | Primena derivata fumarne kiseline u lečenju mitohondrijalnih bolesti | |
| ES2104708T3 (es) | Compuestos heterociclicos terapeuticos. | |
| BR0013897A (pt) | Uso de ácido linoleico conjugado (cla) ou de um seu derivado, composição tópica cosmética ou dermatológica, e, método de tratamento e/ou de profilaxia de celulite e de depósitos de gordura | |
| NO20013367D0 (no) | Colchinolderivater som vaskul¶rskadende midler | |
| ECSP066312A (es) | Derivados piridilo y su uso como agentes terapéuticos | |
| MX2007003508A (es) | Diaril ureas ciclicas adecuadas como inhibidores de tirosina cinasa. | |
| AR034116A2 (es) | Derivados de piperazinas y piperidinas con efecto analgesico, composiciones farmaceuticas que los contienen, uso de los mismos para la fabricacion de un medicamento y un proceso para la preparacion de dichos compuestos | |
| ATE416769T1 (de) | Neue verwendung von glutamat-antagonisten zur behandlung von krebs | |
| BR0209320A (pt) | ésteres de uridina farmaceuticamente ativos | |
| GEP20032973B (en) | 4-Amino Substituted-2-Substituted-1,2,3,4-Tetrahydroquinolines As CETP Inhibitors and Pharmaceutical Compositions Containing the Same | |
| FR2903107B1 (fr) | Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique | |
| ES2149169T3 (es) | Aceite de hongo que contiene acido araquidonico, procedimiento para su produccion y composiciones que contienen dicho aceite. | |
| MX9300786A (es) | Compuestos hipolipidaemicos. | |
| ES2154844T3 (es) | Derivados de hidrocalcona, composiciones cosmeticas que contienen dichos derivados y procedimientos para producir los mismos. | |
| AR070299A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas, usos y composiciones farmaceuticas | |
| BRPI0515482A (pt) | derivados heterocìclicos e seus usos como agentes terapêuticos | |
| ES2152556T3 (es) | Composiciones que contienen derivados del acido hidroperoxieicosatetraenoico y procedimientos de utilizacion en el tratamiento de trastornos de la sequedad ocular. | |
| BR9307142A (pt) | Acido dióico poli-insaturado composição farmacêutica ou cosmética processos para tratar pele humana para alvejar a pele para fazer uma composição antimicrobiana ou de alvejamento da pele e para preparar um ácido dióico insaturado substância de ação terapêutica e usos de um ácido dióico insaturado ou um seu derivado e de ácidos insaturados | |
| ES2142861T3 (es) | Derivados de 4-(1h-2-metilimidazo(4,5-c)piridinilmetil)fenilsulfonamida como antagonistas del paf. | |
| ES2077199T3 (es) | Nuevas piperacinas 1,4-disustituidas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen. | |
| DE60230066D1 (de) | Pharmazeutische zusammensetzung zur behandlung von psoriasis und anderen hautkrankheiten | |
| ES2196049T3 (es) | Uso de 2-(2-alquilfenilamino)oxazolinas y -tiazolinas para la fabricacion de un medicamento con efecto alfa 2 adrenergico. | |
| DE69517050D1 (de) | Verfahren zur stabilisation der polyungesättigten fettsäuren und verwendung dieser stabilisierten produkten in therapie und in kosmetologie | |
| YU234690A (sh) | Supstituisani 4-fenil-4-piperidinkarboksamidi i postupak za njihovo dobijanje | |
| GT200100169A (es) | Compuestos de pirazol, composiciones farmaceuticas y metodos para modular y/o inhibir la actividad de erab/hadh2. |